首页> 外文期刊>Molecular pharmaceutics >Prodrug-Like, PEGylated Protein Toxin Trichosanthin for Reversal of Chemoresistance
【24h】

Prodrug-Like, PEGylated Protein Toxin Trichosanthin for Reversal of Chemoresistance

机译:前药物,聚乙二醇化蛋白毒素Trichosanthin用于逆转化学化学

获取原文
获取原文并翻译 | 示例
       

摘要

Multidrug resistance (MDR) is a main obstacle in cancer chemotherapy. The MDR mechanisms involve P-glycoprotein (P-gp) overexpression, abnormality of,apoptoiis-related protein, and altered expression of drug-targeting proteihs. Therapeutic proteins ate emerging as candidates for Overcoming cancer MDR because of not only their large molecular size that potentially circumvents the P-gp-mediated drug efflux but also their distinctive bioactivity distinguished from small-molecular drugs. Herein we report trichosanthin, a plant protein toxin, possesses synergistic effect with paditaxeI (PTX) in the PTX-resistance A549/T nonsmall cell lung cancer (NSCLC) cells, by reversing PTX-caused caspase 9 phosphorylation and inducing caspase 3-dependent apopiosis. Moreover, via intein-mediated site-specific protein ligation; a matrix metalloproteinase (MMP)-activatable cell-penetrating trichosanthin delivery system was constructed by modification of a cell-penetrating peptide and MMP-2-sensitive PEGylation to overcome the limitation of in vivo application of trichosanthin, by improving the short half-life and poor tumor targeting, as well as immunogenicity. In a mouse model bearing A549/T tumor, the MMP-activatable trichosanthin was further tested for its application for MDR reversal in combination with PTX liposomes. The delivery system showed synergy effect with PTX-loaded liposome in treating MDR cancer in vivo.
机译:多药耐药性(MDR)是癌症化疗的主要障碍。 MDR机制涉及p-糖蛋白(P-GP)过表达,异常,凋亡相关蛋白质,以及改变药物靶向PRODEIH的表达。治疗性蛋白质作为克服癌症MDR的候选者,由于它们的大分子尺寸不仅潜在地避免了P-GP介导的药物流出,而且其独特的生物活性不同于小分子药物。在本文中,通过逆转PTX导致的Caspase 9磷酸化并诱导Caspase 3依赖性阻碍,促进植物蛋白毒素,植物蛋白毒素,植物蛋白毒素中的植物蛋白毒素与帕特西(PTX)具有协同作用。 。此外,通过Intein介导的位点特异性蛋白质结扎;通过改变细胞穿透肽和MMP-2敏感的​​聚乙二醇来构建基质金属蛋白酶(MMP)-ACTIVATABLEALIVATIVET richosanthin递送系统,以通过改善短半衰期和richosanthin的体内应用的限制来构建。可怜的肿瘤靶向,以及免疫原性。在轴承A549 / T肿瘤的小鼠模型中,进一步测试MMP-Actioatable Trichosanthin,其适用于MDR逆转与PTX脂质体的应用。递送系统表明,在体内治疗MDR癌症中的PTX脂质体表现出协同作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号